EGFR and non-small cell lung carcinoma: Although osimertinib is effective as a second‐line administration for patients with EGFR T790M‐positive NSCLC, a considerable number of patients experienced limited responses, and the clinical outcomes for some were not satisfactory [2, 4, 11].